BIOLASE, Inc. (NASDAQ:BIOL) Sees Significant Drop in Short Interest

BIOLASE, Inc. (NASDAQ:BIOL) was the recipient of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 1,970,000 shares, a decrease of 6.2% from the May 31st total of 2,100,000 shares. Based on an average trading volume of 4,720,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 6.1% of the shares of the stock are short sold.

BIOLASE Stock Performance

Shares of NASDAQ BIOL opened at $0.10 on Thursday. BIOLASE has a fifty-two week low of $0.04 and a fifty-two week high of $10.31. The company’s 50 day simple moving average is $0.14 and its 200 day simple moving average is $0.38.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Monday, May 13th. The medical technology company reported ($0.36) EPS for the quarter. The business had revenue of $10.13 million for the quarter. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%.

Institutional Investors Weigh In On BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC raised its stake in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. StockNews.com started coverage on BIOLASE in a report on Saturday, June 29th. They set a “sell” rating on the stock. Maxim Group lowered BIOLASE from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 24th. Finally, Benchmark reiterated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research report on Tuesday, May 14th.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.